Publications by authors named "Luca Bettolini"
Objectives: Genital lichen sclerosus (LS) is a chronic mucocutaneous disorder causing considerable discomfort. Despite this, comprehensive comparison of LS impacts on quality of life (QoL), particularly on men's health or relative to other dermatological conditions like pemphigus, are sparse. This research aims to discern the effects of LS on sexual functionality and overall QoL, benchmarking against pemphigus patients and healthy controls.
View Article and Find Full Text PDFEosinophilic fasciitis (EF) poses a diagnostic challenge owing to its uncommon occurrence and aetiology that remains poorly understood. We report a case of a 79-year-old woman with a prolonged history of breast cancer exhibiting EF with concomitant pelvic metastases. This case underscores EF's potential as an indicator signaling a potential resurgence of cancer, highlighting its significance as a red flag of disease recurrence.
View Article and Find Full Text PDFArticle Synopsis
- Pemphigus is an autoimmune disorder that negatively affects patients' quality of life, particularly their sleep quality, which has been under-researched.
- A study with 156 participants found that those with pemphigus reported higher psychological distress and significantly poorer sleep quality compared to a control group, with specific sleep issues correlated to the severity of their condition.
- The research highlights the importance of considering sleep quality in the overall management of pemphigus, especially since patients with skin manifestations experienced worse sleep than those with oral symptoms.
Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort study.
J Eur Acad Dermatol Venereol
September 2024
Article Synopsis
- A study investigated the effects of dupilumab exposure during pregnancy in women with atopic dermatitis, focusing on safety and outcomes for both mothers and infants.
- Researchers analyzed data from 19 hospitals in Italy, identifying 29 pregnant patients who used dupilumab, with the majority reporting unplanned pregnancies and stopping the medication when they learned of their pregnancy.
- The findings indicated no significant risks associated with dupilumab for adverse pregnancy or neonatal outcomes, suggesting safety for its use in early pregnancy, but further monitoring is recommended for continued use throughout pregnancy.
Article Synopsis
- Ultraviolet (UVA) A1 phototherapy has been an effective treatment for various skin conditions since the 1990s, yet its application remains limited to a few dermatology centers even after 30 years.
- A study at a single center reviewed 740 patients treated from 1998 to 2022, assessing treatment outcomes and side effects, revealing significant improvements in several conditions, including morphea and skin sarcoidosis.
- Despite showing good efficacy, the usage of UVA1 phototherapy has decreased over the years due to multiple factors, including possible changes in clinical practices and alternatives available.
Purpose: Dupilumab, a fully human monoclonal antibody that inhibits the signaling pathways of interleukin (IL)-4 and IL-13, has demonstrated remarkable efficacy in the treatment of atopic dermatitis (AD). Dupilumab has been reported to attenuate itch and reduce several serum markers, including blood lactate dehydrogenase (LDH), blood eosinophil count, and serum total immunoglobulin E (IgE).
Patients And Methods: The present study investigated retrospectively changes in clinical scores and serum biomarker from 175 adults with moderate-to-severe AD treated with dupilumab.